DeCure for Muscular dystrophy, congenital, with cataracts and intellectual disability
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for muscular dystrophy, congenital, with cataracts and intellectual disability — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMuscular dystrophy, congenital, with cataracts and intellectual disability maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for muscular dystrophy, congenital, with cataracts and intellectual disability is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1991 report describes a term newborn male with severe hypotonia, contractures, and dense bilateral cataracts who died at age 3 days of respiratory failure. Autopsy showed skeletal muscle changes consistent with congenital muscular dystrophy and a small focal anomaly of the cerebral cortex. Amino acidopathies, peroxisomal disorders, and intrauterine infection were excluded. The authors state the findings either represent a new syndrome or broaden the spectrum of known congenital muscular dystrophy syndromes with eye and brain anomalies.
A 1998 report describes a patient with a large intragenic dystrophin deletion of exons 17-51 inclusive, associated with congenital cataract and mild Becker muscular dystrophy. The cataract was similar to that described in the mdx mouse. The loss of 68% of the rod domain including hinge 2 and 3 regions did not adversely affect correct localisation of dystrophin or its association with the dystrophin-associated glycoprotein complex. The authors note this observation may have implications for minigenes suitable for gene therapy.
A 2001 case report describes a child with Muscle-Eye-Brain disease, one of three types of congenital muscular dystrophy associated with ocular abnormalities. The child showed severe visual impairment due to progressive myopia and retinal degeneration, a pachygyria-type migration disorder of the brain with a cobblestone cortex, muscular weakness, and severe mental retardation. The authors conclude that ophthalmological assessments are important to help diagnose and follow children with congenital muscular dystrophy.
No drug treatment is mentioned in any of these abstracts. What is missing for this disease group is any clinical trial data, any tested intervention, any patient stratification by genotype, and any funding directed toward a specific therapy. The abstracts provide only natural history observations and a single genetic finding from 1998.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 1998 · 38 citations
Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy
AbstractWe report a patient with a large intragenic dystrophin deletion of exons 17-51 inclusive associated with congenital cataract and mild Becker muscular dystrophy. The cataract was similar to the congenital cataract described in the mdx mouse. The loss of 68% of the rod domain including hinge 2 and 3 regions did not adversely affect the correct localization of the dystrophin and the association with the dystrophin-associated glycoprotein complex. This observation may have implications for minigenes suitable for gene therapy.
AbstractPURPOSE: To describe a child with Muscle-Eye-Brain disease (MEB), one of three types of congenital muscular dystrophy associated with ocular abnormalities. METHODS: Case report. RESULTS: The child showed severe visual impairment due to progressive myopia and retinal degeneration, a pachygyria-type of migration disorder of the brain with a nodular cortical surface, i.e. cobblestone cortex, as well as muscular weakness and severe mental retardation. CONCLUSION: Ophthalmological assessments are important to help to diagnose and follow children with congenital muscular dystrophy.
American Journal of Medical Genetics · 1991 · 7 citations
Lethal congenital muscular dystrophy with cataracts and a minor brain anomaly: New entity or variant of Walker‐Warburg syndrome?
AbstractA term newborn male with severe hypotonia and contractures was found to have dense bilateral cataracts. He died at age 3 days of respiratory failure. Amino acidopathies and disorders of peroxisome function were excluded, and results of serologic studies and placental histopathology, specifically seeking evidence of intrauterine infection, were normal. Autopsy showed changes in the skeletal muscles consistent with congenital muscular dystrophy and a small focal anomaly of the cerebral cortex. These findings either represent a new syndrome or raise further questions about broadening the spectrum of known congenital muscular dystrophy syndromes with associated eye and brain anomalies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
